Key characteristics of the trial participants
| Trial | Number of participants Intensive/conventional (total) | Age (years)* Intensive (SD)/conventional (SD) | Duration of disease at baseline (years)* Intensive (SD)/conventional (SD) | Weight at baseline (kg)* Intensive (SD)/conventional (SD) | BMI at baseline (kg/m2)* Intensive (SD)/conventional (SD) |
|---|---|---|---|---|---|
| DCCT/EDIC 19833–46 | 711/730 (1441) | 27.1 (7.1)/26.5 (7.1) | 6.0 (4.2)/5.7 (4.1) | NR | 23.4 (2.7)/23.5 (2.9) |
| Franklin et al104 | 31 / C1: 28 C2: 33 (92) | 12.6 (11.2–15.4)†/ C1: 12.7 (10.5–14.8) † C2: 14.1 (11.7–15.6) † | 5.4 (2.9–7.7)†/ C1: 3.2 (1.7–6.7)† C2: 4.8 (2.6–8.6)† | NR | 0.44 (0.04–1.04)† / C1: 0.38 (−0.44–0.83)† C2: 0.13 (−0.55–1.0)† ** |
| Hvidovre 198268 | 7/9 (16) | 27 (21–37)†/28 (17–35)† | Newly diagnosed | 93% (80–104) †/87.5% (75–104)† ‡ | NR |
| Kroc 1984112–117 | 35 /35 (70) | 31.9 (10.1)/34.0 (9.5) | 16.5 (6.5)/18.2 (7.1) | 66 (11.8) /68 (11.8) | NR |
| Linn et al 110 | 23/19 (42) | 27 (8)/29 (8) | 7.2 (5.2) days/7.6 (5.6) days | 5.7 (5.2)/5.5 (5.0)¶ | NR |
| Linn et al§69 | NR | NR | NR | NR | NR |
| Microalbuminuria50 5 | 36/34 (70) | 37 (19–59)†/37 (17–58)† | 21 (6–35)/18 (7–34) | NR | 26 (18–40)†/26 (19–34)† |
| Minnesota DCCT 198383–86 | 52/47 (99) | 35 (6)/36 (8) | 23 (6) /21 (5) | NR | 28.2 (8.2)/26 (4.3) |
| Oslo 198673–80 | I1: 15 I2: 15 /15 (45) | I1: 26 (19–42)† I2: 26 (18–38)† / 26 (18–36)† | I1: 12.8 (6.8–20.8)† I2: 12.8 (6.4–23.3)† /12.7 (6.8–12.0)† | I1: 71.7 (10) I2: 68.6 (9.3) / 71.7 (10.5) | NR |
| Oxford 1983111 | 36/38 (74) | 41.6 (11.5)/43.2 (12.6) | 18.1 (5.1)/19.2 (7.1) | NR | 24.9 (3.5)/24.8 (2.4) |
| Perlman et al105 | 7/7 (14) | 13.9 (2.3)/11.6 (1.6) | Newly diagnosed | 43 (12)/41 (12) | NR |
| Service et al81 | 7/8 (15) | 33/31 | 1.1/1.3 | 100%/101% ‡ | NR |
| Shah et al101 | 12/14 (26) | 13.2 (2.4)/13.8 (5.2) | Newly diagnosed | NR | NR |
| Steno 1a 198272 119 120 121 | 18/16 (34) | 35 (21–50)†/32 (24–46)† | 19 (11–33)†/19 (9–27)† | 105% (84–123)†/100% (79–123)† ‡ | NR |
| Steno 1b 198670–72 | 18/18 (36) | 32 (18–48)†/29 (18–47)† | 15 (10–26)†/15 (5–26)† | NR | NR |
| Stockholm 198587–98 | 48/54 (102) | 30.0 (7.5)/31.7 (7.3) | 17.9 (6.4)/16.3 (4.9) | NR | 22.6 (1.9)/22.8 (2.5) |
| Verrillo et al82 | 22/22 (44) | 37 (9.8)/38 (9.0) | 19 (5)/2 (6) | NR | 25.8 (3.5)/26.2 (3.7) |
| Hershey et al102 and White 103 | 17/17 (34) | 13.9 (2.8)/14.3 (2.7) | Newly diagnosed | NR | NR |
*Mean or median.
†Range.
‡Bodyweight % of ideal.
§We only have the study protocol. No results were published and the author was not able to pass any data to us.
¶Weight loss (kg).
**BMI SD score.
BMI, body mass index; C1, conventional group 1; C2, conventional group 2; DCCT/EDIC, Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications; Minnesota DCCT, Minnesota Diabetes Control and Complication Trial; NR, not reported; I1, intensive group 1; I2, intensive group 2.